Hiroyuki Gatanaga

机构：Kumamoto Health Science University, National Center for Global Health and Medicine, Kumamoto University Hospital, Center for Global Health, Kumamoto University · ORCID：0000-0001-9191-9984

发表论文 386 篇 · 总被引 8110 次 · h-index 46

代表论文

• Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial (2026 · The Lancet · 被引 14)
• Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial (2026 · The Lancet HIV · 被引 7)
• Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment (2026 · New England Journal of Medicine · 被引 2)
• Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial (2026 · The Lancet · 被引 1)
• VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment (2026 · Open Forum Infectious Diseases)
• Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan (2026 · Frontiers in Immunology)